Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma

NCT00452569 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00452569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00452569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
February 1, 2006
Completion date
January 1, 2009
Enrollment
499 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma